You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameAlprenolol
Accession NumberDB00866  (APRD00736)
TypeSmall Molecule
GroupsApproved, Withdrawn
DescriptionOne of the adrenergic beta-antagonists used as an antihypertensive, anti-anginal, and anti-arrhythmic agent. Alprenolol is no longer marketed by AstraZeneca, but may still be available in generic varieties.
Structure
Thumb
Synonyms
(RS)-1-(2-allylphenoxy)-3-(isopropylamino)propan-2-ol
1-(2-Allylphenoxy)-3-isopropylamino-2-propanol
1-(O-Allylphenoxy)-3-(isopropylamino)-2-propanol
Alfeprol
Alprenolol
Alprénolol
Alprenolol
Alprenololum
Aprenololo
External Identifiers
  • H 56/28
  • H 561/28
Approved Prescription ProductsNot Available
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
ApllobalAstraZeneca
AptinAstraZeneca
AptineNot Available
Aptol DurilesNot Available
AtenenolTsuruhara Seiyaku
ElpShyh Dar
GubernalNot Available
RegletinNot Available
SkajilolKotobuki Seiyaku
YobirNot Available
Brand mixturesNot Available
Salts
Name/CASStructureProperties
Alprenolol hydrochloride
13707-88-5
Thumb
  • InChI Key: RRCPAXJDDNWJBI-UHFFFAOYSA-N
  • Monoisotopic Mass: 285.1495567
  • Average Mass: 285.81
DBSALT000932
Categories
UNII877K5MQ27W
CAS number13655-52-2
WeightAverage: 249.3486
Monoisotopic: 249.172878985
Chemical FormulaC15H23NO2
InChI KeyPAZJSJFMUHDSTF-UHFFFAOYSA-N
InChI
InChI=1S/C15H23NO2/c1-4-7-13-8-5-6-9-15(13)18-11-14(17)10-16-12(2)3/h4-6,8-9,12,14,16-17H,1,7,10-11H2,2-3H3
IUPAC Name
1-[2-(prop-2-en-1-yl)phenoxy]-3-[(propan-2-yl)amino]propan-2-ol
SMILES
CC(C)NCC(O)COC1=CC=CC=C1CC=C
Pharmacology
IndicationFor the treatment of hypertension, angina, and arrhythmia
Structured Indications Not Available
PharmacodynamicsAlprenolol is a non-selective beta-blocker used in the treatment of hypertension, edema, ventricular tachycardias, and atrial fibrillation. Alprenolol impairs AV node conduction and decreases sinus rate and may also increase plasma triglycerides and decrease HDL-cholesterol levels. Alprenolol is nonpolar and hydrophobic, with low to moderate lipid solubility. Alprenolol has little to no intrinsic sympathomimetic activity and, unlike some other beta-adrenergic blocking agents, alprenolol has little direct myocardial depressant activity and does not have an anesthetic-like membrane-stabilizing action.
Mechanism of actionAlprenolol non-selectively blocks beta-1 adrenergic receptors mainly in the heart, inhibiting the effects of epinephrine and norepinephrine resulting in a decrease in heart rate and blood pressure. Also, with a more minor effect, by binding beta-2 receptors in the juxtaglomerular apparatus, alprenolol inhibits the production of renin, thereby inhibiting angiotensin II and aldosterone production and therefore inhibits the vasoconstriction and water retention due to angiotensin II and aldosterone, respectively.
TargetKindPharmacological actionActionsOrganismUniProt ID
Beta-1 adrenergic receptorProteinyes
antagonist
HumanP08588 details
Beta-2 adrenergic receptorProteinyes
antagonist
HumanP07550 details
5-hydroxytryptamine receptor 1AProteinyes
antagonist
HumanP08908 details
Related Articles
AbsorptionNot Available
Volume of distributionNot Available
Protein binding80-90%
Metabolism

Hepatic. One of the active metabolites, 4-OH-alprenolol, is an active beta-blocker.

SubstrateEnzymesProduct
Alprenolol
Not Available
4-hydroxy-alprenololDetails
Route of eliminationNot Available
Half life2-3 hours
ClearanceNot Available
ToxicityLD50=597.0 mg/kg (Orally in rats)
Affected organisms
  • Humans and other mammals
Pathways
PathwayCategorySMPDB ID
Alprenolol Action PathwayDrug actionSMP00297
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
1,10-Phenanthroline1,10-Phenanthroline may increase the bradycardic activities of Alprenolol.Experimental
4-Methoxyamphetamine4-Methoxyamphetamine may increase the atrioventricular blocking (AV block) activities of Alprenolol.Experimental, Illicit
7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE may increase the hypotensive activities of Alprenolol.Experimental
AbirateroneThe serum concentration of Alprenolol can be increased when it is combined with Abiraterone.Approved
AcebutololAlprenolol may increase the hypotensive activities of Acebutolol.Approved
AceclofenacAceclofenac may decrease the antihypertensive activities of Alprenolol.Approved
AcepromazineAcepromazine may increase the hypotensive activities of Alprenolol.Approved, Vet Approved
AceprometazineAceprometazine may increase the hypotensive activities of Alprenolol.Approved
AcetohexamideAlprenolol may increase the hypoglycemic activities of Acetohexamide.Withdrawn
AcetovanilloneAcetovanillone may decrease the antihypertensive activities of Alprenolol.Investigational
AcetylcholineThe risk or severity of adverse effects can be increased when Alprenolol is combined with Acetylcholine.Approved
AcetyldigitoxinAlprenolol may increase the bradycardic activities of Acetyldigitoxin.Approved
Acetylsalicylic acidAcetylsalicylic acid may decrease the antihypertensive activities of Alprenolol.Approved, Vet Approved
AdapaleneAdapalene may decrease the antihypertensive activities of Alprenolol.Approved
AgmatineAgmatine may increase the atrioventricular blocking (AV block) activities of Alprenolol.Experimental, Investigational
AlfentanilAlfentanil may increase the bradycardic activities of Alprenolol.Approved, Illicit
AlfuzosinAlfuzosin may increase the hypotensive activities of Alprenolol.Approved, Investigational
AlimemazineAlimemazine may increase the hypotensive activities of Alprenolol.Approved, Vet Approved
AliskirenAlprenolol may increase the hypotensive activities of Aliskiren.Approved, Investigational
AmbenoniumAmbenonium may increase the bradycardic activities of Alprenolol.Approved
AmbrisentanAlprenolol may increase the hypotensive activities of Ambrisentan.Approved, Investigational
Ambroxol acefyllinateAlprenolol may decrease the bronchodilatory activities of Ambroxol acefyllinate.Experimental
AmifostineAlprenolol may increase the hypotensive activities of Amifostine.Approved, Investigational
AminophyllineAlprenolol may decrease the bronchodilatory activities of Aminophylline.Approved
AmiodaroneAmiodarone may increase the bradycardic activities of Alprenolol.Approved, Investigational
AmlodipineAmlodipine may increase the hypotensive activities of Alprenolol.Approved
AmobarbitalThe serum concentration of Alprenolol can be decreased when it is combined with Amobarbital.Approved, Illicit
AmodiaquineThe metabolism of Alprenolol can be decreased when combined with Amodiaquine.Approved
AnisodamineAnisodamine may decrease the antihypertensive activities of Alprenolol.Investigational
AntipyrineAntipyrine may decrease the antihypertensive activities of Alprenolol.Approved
AnvirzelAlprenolol may increase the bradycardic activities of Anvirzel.Investigational
ApomorphineApomorphine may increase the atrioventricular blocking (AV block) activities of Alprenolol.Approved, Investigational
ApremilastApremilast may decrease the antihypertensive activities of Alprenolol.Approved, Investigational
ArbutamineAlprenolol may decrease the bronchodilatory activities of Arbutamine.Approved
ArecolineThe risk or severity of adverse effects can be increased when Alprenolol is combined with Arecoline.Experimental
ArformoterolAlprenolol may decrease the bronchodilatory activities of Arformoterol.Approved, Investigational
ArtemetherThe metabolism of Alprenolol can be decreased when combined with Artemether.Approved
AtenololAtenolol may increase the hypotensive activities of Alprenolol.Approved
AtomoxetineThe metabolism of Alprenolol can be decreased when combined with Atomoxetine.Approved
AzapropazoneAzapropazone may decrease the antihypertensive activities of Alprenolol.Withdrawn
AzelastineAzelastine may decrease the antihypertensive activities of Alprenolol.Approved
BalsalazideBalsalazide may decrease the antihypertensive activities of Alprenolol.Approved, Investigational
BambuterolAlprenolol may decrease the bronchodilatory activities of Bambuterol.Approved
BarbexacloneThe serum concentration of Alprenolol can be decreased when it is combined with Barbexaclone.Experimental
BarbitalThe serum concentration of Alprenolol can be decreased when it is combined with Barbital.Illicit
BenazeprilBenazepril may increase the hypotensive activities of Alprenolol.Approved, Investigational
BendroflumethiazideBendroflumethiazide may increase the hypotensive activities of Alprenolol.Approved
BenmoxinBenmoxin may increase the hypotensive activities of Alprenolol.Withdrawn
BenoxaprofenBenoxaprofen may decrease the antihypertensive activities of Alprenolol.Withdrawn
BenzphetamineBenzphetamine may increase the atrioventricular blocking (AV block) activities of Alprenolol.Approved, Illicit
BepridilAlprenolol may increase the hypotensive activities of Bepridil.Approved, Withdrawn
BetaxololThe metabolism of Alprenolol can be decreased when combined with Betaxolol.Approved
BethanecholThe risk or severity of adverse effects can be increased when Alprenolol is combined with Bethanechol.Approved
BethanidineBethanidine may increase the atrioventricular blocking (AV block) activities of Alprenolol.Approved
Betulinic AcidBetulinic Acid may decrease the antihypertensive activities of Alprenolol.Investigational
BimatoprostAlprenolol may increase the hypotensive activities of Bimatoprost.Approved, Investigational
BisoprololBisoprolol may increase the hypotensive activities of Alprenolol.Approved
BL-1020BL-1020 may increase the hypotensive activities of Alprenolol.Investigational
BosentanBosentan may increase the hypotensive activities of Alprenolol.Approved, Investigational
BretyliumAlprenolol may increase the hypotensive activities of Bretylium.Approved
BrimonidineBrimonidine may increase the atrioventricular blocking (AV block) activities of Alprenolol.Approved
BrimonidineBrimonidine may increase the antihypertensive activities of Alprenolol.Approved
BromfenacBromfenac may decrease the antihypertensive activities of Alprenolol.Approved
BromocriptineBromocriptine may increase the atrioventricular blocking (AV block) activities of Alprenolol.Approved, Investigational
BucillamineBucillamine may decrease the antihypertensive activities of Alprenolol.Investigational
BucindololAlprenolol may increase the orthostatic hypotensive activities of Bucindolol.Investigational
BupivacaineThe serum concentration of Bupivacaine can be increased when it is combined with Alprenolol.Approved, Investigational
BupranololAlprenolol may increase the hypotensive activities of Bupranolol.Approved
BupropionThe metabolism of Alprenolol can be decreased when combined with Bupropion.Approved
CabergolineAlprenolol may increase the vasoconstricting activities of Cabergoline.Approved
CandesartanCandesartan may increase the hypotensive activities of Alprenolol.Approved
CandoxatrilCandoxatril may increase the hypotensive activities of Alprenolol.Experimental
CaptoprilAlprenolol may increase the hypotensive activities of Captopril.Approved
CarbacholThe risk or severity of adverse effects can be increased when Alprenolol is combined with Carbachol.Approved
CaroxazoneCaroxazone may increase the hypotensive activities of Alprenolol.Withdrawn
CarprofenCarprofen may decrease the antihypertensive activities of Alprenolol.Approved, Vet Approved, Withdrawn
CarteololCarteolol may increase the hypotensive activities of Alprenolol.Approved
CarvedilolAlprenolol may increase the orthostatic hypotensive activities of Carvedilol.Approved, Investigational
CastanospermineCastanospermine may decrease the antihypertensive activities of Alprenolol.Experimental
CelecoxibThe metabolism of Alprenolol can be decreased when combined with Celecoxib.Approved, Investigational
CeliprololAlprenolol may decrease the bronchodilatory activities of Celiprolol.Approved, Investigational
CevimelineThe risk or severity of adverse effects can be increased when Alprenolol is combined with Cevimeline.Approved
ChloroquineThe metabolism of Alprenolol can be decreased when combined with Chloroquine.Approved, Vet Approved
ChlorothiazideAlprenolol may increase the hypotensive activities of Chlorothiazide.Approved, Vet Approved
ChlorpromazineThe metabolism of Alprenolol can be decreased when combined with Chlorpromazine.Approved, Vet Approved
ChlorpropamideAlprenolol may increase the hypoglycemic activities of Chlorpropamide.Approved
ChlorthalidoneChlorthalidone may increase the hypotensive activities of Alprenolol.Approved
CholecalciferolThe metabolism of Alprenolol can be decreased when combined with Cholecalciferol.Approved, Nutraceutical
CilazaprilAlprenolol may increase the hypotensive activities of Cilazapril.Approved
CimetidineThe metabolism of Alprenolol can be decreased when combined with Cimetidine.Approved
CinacalcetThe metabolism of Alprenolol can be decreased when combined with Cinacalcet.Approved
CitalopramThe metabolism of Alprenolol can be decreased when combined with Citalopram.Approved
ClemastineThe metabolism of Alprenolol can be decreased when combined with Clemastine.Approved
ClenbuterolAlprenolol may decrease the bronchodilatory activities of Clenbuterol.Approved, Vet Approved
ClobazamThe metabolism of Alprenolol can be decreased when combined with Clobazam.Approved, Illicit
ClomipramineThe metabolism of Alprenolol can be decreased when combined with Clomipramine.Approved, Vet Approved
ClonidineClonidine may increase the atrioventricular blocking (AV block) activities of Alprenolol.Approved
ClonixinClonixin may decrease the antihypertensive activities of Alprenolol.Approved
ClotrimazoleThe metabolism of Alprenolol can be decreased when combined with Clotrimazole.Approved, Vet Approved
ClozapineThe metabolism of Alprenolol can be decreased when combined with Clozapine.Approved
CobicistatThe serum concentration of Alprenolol can be increased when it is combined with Cobicistat.Approved
CocaineThe metabolism of Alprenolol can be decreased when combined with Cocaine.Approved, Illicit
CoumaphosCoumaphos may increase the bradycardic activities of Alprenolol.Vet Approved
CryptenamineCryptenamine may increase the hypotensive activities of Alprenolol.Approved
CurcuminCurcumin may decrease the antihypertensive activities of Alprenolol.Investigational
CyclothiazideCyclothiazide may increase the hypotensive activities of Alprenolol.Approved
D-LimoneneD-Limonene may decrease the antihypertensive activities of Alprenolol.Investigational
DapoxetineThe serum concentration of Alprenolol can be increased when it is combined with Dapoxetine.Investigational
DarifenacinThe metabolism of Alprenolol can be decreased when combined with Darifenacin.Approved, Investigational
DarunavirThe serum concentration of Alprenolol can be increased when it is combined with Darunavir.Approved
DebrisoquinAlprenolol may increase the hypotensive activities of Debrisoquin.Approved
DecamethoniumDecamethonium may increase the bradycardic activities of Alprenolol.Approved
DelavirdineThe metabolism of Alprenolol can be decreased when combined with Delavirdine.Approved
DemecariumDemecarium may increase the bradycardic activities of Alprenolol.Approved
DeserpidineAlprenolol may increase the hypotensive activities of Deserpidine.Approved
DesipramineThe metabolism of Alprenolol can be decreased when combined with Desipramine.Approved
DeslanosideAlprenolol may increase the bradycardic activities of Deslanoside.Approved
DesvenlafaxineThe serum concentration of Alprenolol can be increased when it is combined with Desvenlafaxine.Approved
DexmedetomidineDexmedetomidine may increase the atrioventricular blocking (AV block) activities of Alprenolol.Approved, Vet Approved
DiazoxideDiazoxide may increase the hypotensive activities of Alprenolol.Approved
DichlorvosDichlorvos may increase the bradycardic activities of Alprenolol.Vet Approved
DiclofenacDiclofenac may decrease the antihypertensive activities of Alprenolol.Approved, Vet Approved
DiflunisalDiflunisal may decrease the antihypertensive activities of Alprenolol.Approved
DigitoxinAlprenolol may increase the bradycardic activities of Digitoxin.Approved
DigoxinAlprenolol may increase the bradycardic activities of Digoxin.Approved
DihydralazineAlprenolol may increase the hypotensive activities of Dihydralazine.Investigational
DihydroergotamineDihydroergotamine may increase the atrioventricular blocking (AV block) activities of Alprenolol.Approved
DiltiazemDiltiazem may increase the hypotensive activities of Alprenolol.Approved
DiphenhydramineThe metabolism of Alprenolol can be decreased when combined with Diphenhydramine.Approved
DipivefrinAlprenolol may decrease the bronchodilatory activities of Dipivefrin.Approved
DipyridamoleDipyridamole may increase the bradycardic activities of Alprenolol.Approved
DisopyramideDisopyramide may increase the bradycardic activities of Alprenolol.Approved
DobutamineAlprenolol may decrease the bronchodilatory activities of Dobutamine.Approved
DonepezilDonepezil may increase the bradycardic activities of Alprenolol.Approved
DorzolamideAlprenolol may increase the hypotensive activities of Dorzolamide.Approved
DoxazosinAlprenolol may increase the orthostatic hypotensive activities of Doxazosin.Approved
DronedaroneDronedarone may increase the bradycardic activities of Alprenolol.Approved
DroxicamDroxicam may decrease the antihypertensive activities of Alprenolol.Approved
DroxidopaAlprenolol may decrease the bronchodilatory activities of Droxidopa.Approved, Investigational
DuloxetineThe metabolism of Alprenolol can be decreased when combined with Duloxetine.Approved
DuvelisibDuvelisib may decrease the antihypertensive activities of Alprenolol.Investigational
DyphyllineAlprenolol may decrease the bronchodilatory activities of Dyphylline.Approved
E6201E6201 may decrease the antihypertensive activities of Alprenolol.Investigational
EbselenEbselen may decrease the antihypertensive activities of Alprenolol.Investigational
EchothiophateEchothiophate may increase the bradycardic activities of Alprenolol.Approved
EdrophoniumEdrophonium may increase the bradycardic activities of Alprenolol.Approved
EfonidipineAlprenolol may increase the hypotensive activities of Efonidipine.Approved
EliglustatThe metabolism of Alprenolol can be decreased when combined with Eliglustat.Approved
EnalaprilEnalapril may increase the hypotensive activities of Alprenolol.Approved, Vet Approved
EnalaprilatAlprenolol may increase the hypotensive activities of Enalaprilat.Approved
EphedraAlprenolol may decrease the bronchodilatory activities of Ephedra.Approved, Nutraceutical, Withdrawn
EPIBATIDINEThe risk or severity of adverse effects can be increased when Alprenolol is combined with EPIBATIDINE.Experimental
EpinephrineAlprenolol may decrease the bronchodilatory activities of Epinephrine.Approved, Vet Approved
EpirizoleEpirizole may decrease the antihypertensive activities of Alprenolol.Approved
EpoprostenolAlprenolol may increase the hypotensive activities of Epoprostenol.Approved
EprosartanAlprenolol may increase the hypotensive activities of Eprosartan.Approved
Ergoloid mesylateAlprenolol may increase the vasoconstricting activities of Ergoloid mesylate.Approved
ErgonovineAlprenolol may increase the vasoconstricting activities of Ergonovine.Approved
ErgotamineErgotamine may increase the atrioventricular blocking (AV block) activities of Alprenolol.Approved
EtanerceptEtanercept may decrease the antihypertensive activities of Alprenolol.Approved, Investigational
EtodolacEtodolac may decrease the antihypertensive activities of Alprenolol.Approved, Investigational, Vet Approved
EtofenamateEtofenamate may decrease the antihypertensive activities of Alprenolol.Approved
EtomidateEtomidate may increase the atrioventricular blocking (AV block) activities of Alprenolol.Approved
EtoperidoneThe serum concentration of Alprenolol can be increased when it is combined with Etoperidone.Approved
EtoricoxibEtoricoxib may decrease the antihypertensive activities of Alprenolol.Approved, Investigational
Evening primrose oilEvening primrose oil may decrease the antihypertensive activities of Alprenolol.Approved
exisulindexisulind may decrease the antihypertensive activities of Alprenolol.Investigational
FelodipineAlprenolol may increase the hypotensive activities of Felodipine.Approved, Investigational
FenbufenFenbufen may decrease the antihypertensive activities of Alprenolol.Approved
FenoldopamFenoldopam may increase the hypotensive activities of Alprenolol.Approved
FenoprofenFenoprofen may decrease the antihypertensive activities of Alprenolol.Approved
FenoterolAlprenolol may decrease the bronchodilatory activities of Fenoterol.Approved
FentanylFentanyl may increase the bradycardic activities of Alprenolol.Approved, Illicit, Investigational, Vet Approved
FenthionFenthion may increase the bradycardic activities of Alprenolol.Vet Approved
FingolimodAlprenolol may increase the bradycardic activities of Fingolimod.Approved, Investigational
FloctafenineThe risk or severity of adverse effects can be increased when Floctafenine is combined with Alprenolol.Approved, Withdrawn
FlunixinFlunixin may decrease the antihypertensive activities of Alprenolol.Vet Approved
FluoxetineThe metabolism of Alprenolol can be decreased when combined with Fluoxetine.Approved, Vet Approved
FluphenazineFluphenazine may increase the hypotensive activities of Alprenolol.Approved
FlurbiprofenFlurbiprofen may decrease the antihypertensive activities of Alprenolol.Approved, Investigational
FluvoxamineThe metabolism of Alprenolol can be decreased when combined with Fluvoxamine.Approved, Investigational
FormoterolAlprenolol may decrease the bronchodilatory activities of Formoterol.Approved, Investigational
FosinoprilFosinopril may increase the hypotensive activities of Alprenolol.Approved
FurazolidoneFurazolidone may increase the hypotensive activities of Alprenolol.Approved, Vet Approved
GalantamineGalantamine may increase the bradycardic activities of Alprenolol.Approved
Gallamine TriethiodideGallamine Triethiodide may increase the bradycardic activities of Alprenolol.Approved
Ginkgo bilobaGinkgo biloba may increase the bradycardic activities of Alprenolol.Approved, Nutraceutical
GlibornurideAlprenolol may increase the hypoglycemic activities of Glibornuride.Withdrawn
GliclazideAlprenolol may increase the hypoglycemic activities of Gliclazide.Approved
GlimepirideAlprenolol may increase the hypoglycemic activities of Glimepiride.Approved
GlipizideAlprenolol may increase the hypoglycemic activities of Glipizide.Approved
GliquidoneAlprenolol may increase the hypoglycemic activities of Gliquidone.Approved
GlisoxepideAlprenolol may increase the hypoglycemic activities of Glisoxepide.Approved
GlyburideAlprenolol may increase the hypoglycemic activities of Glyburide.Approved
GTS-21The risk or severity of adverse effects can be increased when Alprenolol is combined with GTS-21.Investigational
GuanabenzGuanabenz may increase the atrioventricular blocking (AV block) activities of Alprenolol.Approved
GuanadrelGuanadrel may increase the hypotensive activities of Alprenolol.Approved
GuanethidineAlprenolol may increase the hypotensive activities of Guanethidine.Approved
GuanfacineGuanfacine may increase the atrioventricular blocking (AV block) activities of Alprenolol.Approved, Investigational
HaloperidolThe metabolism of Alprenolol can be decreased when combined with Haloperidol.Approved
HexamethoniumAlprenolol may increase the hypotensive activities of Hexamethonium.Experimental
HexobarbitalThe serum concentration of Alprenolol can be decreased when it is combined with Hexobarbital.Approved
HigenamineHigenamine may decrease the antihypertensive activities of Alprenolol.Investigational
HMPL-004HMPL-004 may decrease the antihypertensive activities of Alprenolol.Investigational
Huperzine AHuperzine A may increase the bradycardic activities of Alprenolol.Investigational
HydracarbazineHydracarbazine may increase the hypotensive activities of Alprenolol.Approved
HydralazineAlprenolol may increase the hypotensive activities of Hydralazine.Approved
HydrochlorothiazideAlprenolol may increase the hypotensive activities of Hydrochlorothiazide.Approved, Vet Approved
HydroflumethiazideHydroflumethiazide may increase the hypotensive activities of Alprenolol.Approved
HydroxychloroquineThe metabolism of Alprenolol can be decreased when combined with Hydroxychloroquine.Approved
IbuprofenIbuprofen may decrease the antihypertensive activities of Alprenolol.Approved
IbuproxamIbuproxam may decrease the antihypertensive activities of Alprenolol.Withdrawn
IcatibantIcatibant may decrease the antihypertensive activities of Alprenolol.Approved
IloprostIloprost may increase the hypotensive activities of Alprenolol.Approved, Investigational
ImidaprilAlprenolol may increase the hypotensive activities of Imidapril.Investigational
ImipramineThe metabolism of Alprenolol can be decreased when combined with Imipramine.Approved
IndacaterolAlprenolol may decrease the bronchodilatory activities of Indacaterol.Approved
IndalpineThe serum concentration of Alprenolol can be increased when it is combined with Indalpine.Investigational, Withdrawn
IndapamideIndapamide may increase the hypotensive activities of Alprenolol.Approved
IndenololAlprenolol may increase the hypotensive activities of Indenolol.Withdrawn
IndinavirThe metabolism of Alprenolol can be decreased when combined with Indinavir.Approved
IndomethacinIndomethacin may decrease the antihypertensive activities of Alprenolol.Approved, Investigational
IndoprofenIndoprofen may decrease the antihypertensive activities of Alprenolol.Withdrawn
IndoraminAlprenolol may increase the orthostatic hypotensive activities of Indoramin.Withdrawn
Insulin PorkAlprenolol may increase the hypoglycemic activities of Insulin Pork.Approved
IproclozideIproclozide may increase the hypotensive activities of Alprenolol.Withdrawn
IproniazidIproniazid may increase the hypotensive activities of Alprenolol.Withdrawn
IrbesartanAlprenolol may increase the hypotensive activities of Irbesartan.Approved, Investigational
IsocarboxazidIsocarboxazid may increase the hypotensive activities of Alprenolol.Approved
IsoetarineAlprenolol may decrease the bronchodilatory activities of Isoetarine.Approved
IsoflurophateIsoflurophate may increase the bradycardic activities of Alprenolol.Approved, Withdrawn
IsoniazidThe metabolism of Alprenolol can be decreased when combined with Isoniazid.Approved
IsoprenalineAlprenolol may decrease the bronchodilatory activities of Isoprenaline.Approved
IsoxicamIsoxicam may decrease the antihypertensive activities of Alprenolol.Withdrawn
IsradipineIsradipine may increase the hypotensive activities of Alprenolol.Approved
KebuzoneKebuzone may decrease the antihypertensive activities of Alprenolol.Experimental
KetanserinAlprenolol may increase the hypotensive activities of Ketanserin.Investigational
KetoconazoleThe metabolism of Alprenolol can be decreased when combined with Ketoconazole.Approved, Investigational
KetoprofenKetoprofen may decrease the antihypertensive activities of Alprenolol.Approved, Vet Approved
KetorolacKetorolac may decrease the antihypertensive activities of Alprenolol.Approved
LabetalolAlprenolol may increase the orthostatic hypotensive activities of Labetalol.Approved
LacidipineAlprenolol may increase the hypotensive activities of Lacidipine.Approved
LatanoprostLatanoprost may increase the hypotensive activities of Alprenolol.Approved, Investigational
LeflunomideLeflunomide may decrease the antihypertensive activities of Alprenolol.Approved, Investigational
LercanidipineLercanidipine may increase the hypotensive activities of Alprenolol.Approved, Investigational
LevomilnacipranThe serum concentration of Alprenolol can be increased when it is combined with Levomilnacipran.Approved
LidocaineThe serum concentration of Lidocaine can be increased when it is combined with Alprenolol.Approved, Vet Approved
LisinoprilLisinopril may increase the hypotensive activities of Alprenolol.Approved, Investigational
LisofyllineLisofylline may decrease the antihypertensive activities of Alprenolol.Investigational
LobelineThe risk or severity of adverse effects can be increased when Alprenolol is combined with Lobeline.Investigational
LofexidineLofexidine may increase the atrioventricular blocking (AV block) activities of Alprenolol.Approved, Investigational
LopinavirThe metabolism of Alprenolol can be decreased when combined with Lopinavir.Approved
LorcaserinThe metabolism of Alprenolol can be decreased when combined with Lorcaserin.Approved
LornoxicamLornoxicam may decrease the antihypertensive activities of Alprenolol.Approved
LosartanLosartan may increase the hypotensive activities of Alprenolol.Approved
LoxoprofenLoxoprofen may decrease the antihypertensive activities of Alprenolol.Approved
LumefantrineThe metabolism of Alprenolol can be decreased when combined with Lumefantrine.Approved
LumiracoxibLumiracoxib may decrease the antihypertensive activities of Alprenolol.Approved, Investigational
MacitentanAlprenolol may increase the hypotensive activities of Macitentan.Approved
Magnesium salicylateMagnesium salicylate may decrease the antihypertensive activities of Alprenolol.Approved
MalathionMalathion may increase the bradycardic activities of Alprenolol.Approved, Investigational
ManidipineAlprenolol may increase the hypotensive activities of Manidipine.Approved
MasoprocolMasoprocol may decrease the antihypertensive activities of Alprenolol.Approved
MebanazineMebanazine may increase the hypotensive activities of Alprenolol.Withdrawn
MecamylamineMecamylamine may increase the hypotensive activities of Alprenolol.Approved
Meclofenamic acidMeclofenamic acid may decrease the antihypertensive activities of Alprenolol.Approved, Vet Approved
Mefenamic acidMefenamic acid may decrease the antihypertensive activities of Alprenolol.Approved
MefloquineMefloquine may increase the bradycardic activities of Alprenolol.Approved
MeloxicamMeloxicam may decrease the antihypertensive activities of Alprenolol.Approved, Vet Approved
MemantineMemantine may increase the bradycardic activities of Alprenolol.Approved, Investigational
MepivacaineThe serum concentration of Mepivacaine can be increased when it is combined with Alprenolol.Approved, Vet Approved
MesalazineMesalazine may decrease the antihypertensive activities of Alprenolol.Approved
MesoridazineMesoridazine may increase the hypotensive activities of Alprenolol.Approved
MetamizoleMetamizole may decrease the antihypertensive activities of Alprenolol.Withdrawn
MethacholineThe risk or severity of adverse effects can be increased when Alprenolol is combined with Methacholine.Approved
MethadoneThe metabolism of Alprenolol can be decreased when combined with Methadone.Approved
MethamphetamineMethamphetamine may increase the atrioventricular blocking (AV block) activities of Alprenolol.Approved, Illicit
Methanesulfonyl FluorideMethanesulfonyl Fluoride may increase the bradycardic activities of Alprenolol.Investigational
MethohexitalThe serum concentration of Alprenolol can be decreased when it is combined with Methohexital.Approved
MethotrimeprazineThe metabolism of Alprenolol can be decreased when combined with Methotrimeprazine.Approved
MethyldopaAlprenolol may increase the hypotensive activities of Methyldopa.Approved
Methylene blueMethylene blue may increase the hypotensive activities of Alprenolol.Investigational
MethylphenidateMethylphenidate may decrease the antihypertensive activities of Alprenolol.Approved, Investigational
MethylphenobarbitalThe serum concentration of Alprenolol can be decreased when it is combined with Methylphenobarbital.Approved
MetipranololAlprenolol may increase the hypotensive activities of Metipranolol.Approved
MetolazoneMetolazone may increase the hypotensive activities of Alprenolol.Approved
MetoprololThe metabolism of Alprenolol can be decreased when combined with Metoprolol.Approved, Investigational
MetyrosineAlprenolol may increase the hypotensive activities of Metyrosine.Approved
MibefradilAlprenolol may increase the hypotensive activities of Mibefradil.Withdrawn
MidodrineAlprenolol may increase the bradycardic activities of Midodrine.Approved
MilnacipranThe serum concentration of Alprenolol can be increased when it is combined with Milnacipran.Approved
MinaprineMinaprine may increase the bradycardic activities of Alprenolol.Approved
MinoxidilMinoxidil may increase the hypotensive activities of Alprenolol.Approved
MirabegronThe metabolism of Alprenolol can be decreased when combined with Mirabegron.Approved
MizoribineMizoribine may decrease the antihypertensive activities of Alprenolol.Investigational
MoclobemideMoclobemide may increase the hypotensive activities of Alprenolol.Approved
MoexiprilMoexipril may increase the hypotensive activities of Alprenolol.Approved
MolsidomineMolsidomine may increase the hypotensive activities of Alprenolol.Approved
MoricizineMoricizine may increase the hypotensive activities of Alprenolol.Approved, Withdrawn
MoxonidineAlprenolol may increase the hypotensive activities of Moxonidine.Approved
Mycophenolate mofetilMycophenolate mofetil may decrease the antihypertensive activities of Alprenolol.Approved, Investigational
Mycophenolic acidMycophenolic acid may decrease the antihypertensive activities of Alprenolol.Approved
NabumetoneNabumetone may decrease the antihypertensive activities of Alprenolol.Approved
NadololAlprenolol may increase the hypotensive activities of Nadolol.Approved
NafamostatNafamostat may decrease the antihypertensive activities of Alprenolol.Investigational
NaftifineNaftifine may decrease the antihypertensive activities of Alprenolol.Approved
NaftopidilAlprenolol may increase the hypotensive activities of Naftopidil.Investigational
NaphazolineNaphazoline may increase the atrioventricular blocking (AV block) activities of Alprenolol.Approved
NaproxenNaproxen may decrease the antihypertensive activities of Alprenolol.Approved, Vet Approved
NCX 4016NCX 4016 may decrease the antihypertensive activities of Alprenolol.Investigational
NebivololAlprenolol may increase the hypotensive activities of Nebivolol.Approved, Investigational
NefazodoneThe serum concentration of Alprenolol can be increased when it is combined with Nefazodone.Approved, Withdrawn
NeostigmineNeostigmine may increase the bradycardic activities of Alprenolol.Approved, Vet Approved
NepafenacNepafenac may decrease the antihypertensive activities of Alprenolol.Approved
NevirapineThe metabolism of Alprenolol can be decreased when combined with Nevirapine.Approved
NialamideNialamide may increase the hypotensive activities of Alprenolol.Withdrawn
NicardipineThe metabolism of Alprenolol can be decreased when combined with Nicardipine.Approved
NicorandilAlprenolol may increase the hypotensive activities of Nicorandil.Approved
NicotineThe risk or severity of adverse effects can be increased when Alprenolol is combined with Nicotine.Approved
Nicotine bitartrateThe risk or severity of adverse effects can be increased when Alprenolol is combined with Nicotine bitartrate.Approved
NifedipineNifedipine may increase the hypotensive activities of Alprenolol.Approved
Niflumic AcidNiflumic Acid may decrease the antihypertensive activities of Alprenolol.Approved
NiguldipineAlprenolol may increase the hypotensive activities of Niguldipine.Experimental
NilotinibThe metabolism of Alprenolol can be decreased when combined with Nilotinib.Approved, Investigational
NilvadipineAlprenolol may increase the hypotensive activities of Nilvadipine.Approved
NimesulideNimesulide may decrease the antihypertensive activities of Alprenolol.Approved, Withdrawn
NimodipineNimodipine may increase the hypotensive activities of Alprenolol.Approved
NisoldipineNisoldipine may increase the hypotensive activities of Alprenolol.Approved
NitrendipineAlprenolol may increase the hypotensive activities of Nitrendipine.Approved
NitroaspirinNitroaspirin may decrease the antihypertensive activities of Alprenolol.Investigational
NitroprussideNitroprusside may increase the hypotensive activities of Alprenolol.Approved
NorepinephrineAlprenolol may decrease the bronchodilatory activities of Norepinephrine.Approved
ObinutuzumabAlprenolol may increase the hypotensive activities of Obinutuzumab.Approved
OctamoxinOctamoxin may increase the hypotensive activities of Alprenolol.Withdrawn
OlmesartanOlmesartan may increase the hypotensive activities of Alprenolol.Approved, Investigational
OlodaterolAlprenolol may decrease the bronchodilatory activities of Olodaterol.Approved
OlopatadineOlopatadine may decrease the antihypertensive activities of Alprenolol.Approved
OlsalazineOlsalazine may decrease the antihypertensive activities of Alprenolol.Approved
OmapatrilatAlprenolol may increase the hypotensive activities of Omapatrilat.Investigational
OrciprenalineAlprenolol may decrease the bronchodilatory activities of Orciprenaline.Approved
OrgoteinOrgotein may decrease the antihypertensive activities of Alprenolol.Vet Approved
OuabainAlprenolol may increase the bradycardic activities of Ouabain.Approved
OxaprozinOxaprozin may decrease the antihypertensive activities of Alprenolol.Approved
OxprenololAlprenolol may increase the hypotensive activities of Oxprenolol.Approved
OxymetazolineOxymetazoline may increase the atrioventricular blocking (AV block) activities of Alprenolol.Approved
OxyphenbutazoneOxyphenbutazone may decrease the antihypertensive activities of Alprenolol.Withdrawn
PaliperidonePaliperidone may increase the atrioventricular blocking (AV block) activities of Alprenolol.Approved
PanobinostatThe serum concentration of Alprenolol can be increased when it is combined with Panobinostat.Approved, Investigational
ParecoxibParecoxib may decrease the antihypertensive activities of Alprenolol.Approved
PargylinePargyline may increase the hypotensive activities of Alprenolol.Approved
ParoxetineThe metabolism of Alprenolol can be decreased when combined with Paroxetine.Approved, Investigational
Peginterferon alfa-2bThe serum concentration of Alprenolol can be decreased when it is combined with Peginterferon alfa-2b.Approved
PenbutololAlprenolol may increase the hypotensive activities of Penbutolol.Approved, Investigational
PentobarbitalThe serum concentration of Alprenolol can be decreased when it is combined with Pentobarbital.Approved, Vet Approved
PentoliniumAlprenolol may increase the hypotensive activities of Pentolinium.Approved
PentoxifyllinePentoxifylline may increase the hypotensive activities of Alprenolol.Approved, Investigational
PerazinePerazine may increase the hypotensive activities of Alprenolol.Investigational
PergolidePergolide may increase the atrioventricular blocking (AV block) activities of Alprenolol.Approved, Vet Approved, Withdrawn
PerindoprilPerindopril may increase the hypotensive activities of Alprenolol.Approved
PerphenazinePerphenazine may increase the hypotensive activities of Alprenolol.Approved
PhenelzinePhenelzine may increase the hypotensive activities of Alprenolol.Approved
PheniprazinePheniprazine may increase the hypotensive activities of Alprenolol.Withdrawn
PhenobarbitalThe serum concentration of Alprenolol can be decreased when it is combined with Phenobarbital.Approved
PhenoxybenzamineAlprenolol may increase the hypotensive activities of Phenoxybenzamine.Approved
PhenoxypropazinePhenoxypropazine may increase the hypotensive activities of Alprenolol.Withdrawn
PhentolaminePhentolamine may increase the hypotensive activities of Alprenolol.Approved
PhenylbutazonePhenylbutazone may decrease the antihypertensive activities of Alprenolol.Approved, Vet Approved
PhenylpropanolamineAlprenolol may decrease the bronchodilatory activities of Phenylpropanolamine.Approved, Vet Approved, Withdrawn
PhysostigminePhysostigmine may increase the bradycardic activities of Alprenolol.Approved
PilocarpineThe risk or severity of adverse effects can be increased when Alprenolol is combined with Pilocarpine.Approved
PimecrolimusPimecrolimus may decrease the antihypertensive activities of Alprenolol.Approved, Investigational
PinacidilAlprenolol may increase the hypotensive activities of Pinacidil.Withdrawn
PindololAlprenolol may increase the hypotensive activities of Pindolol.Approved
PirbuterolAlprenolol may decrease the bronchodilatory activities of Pirbuterol.Approved
PirfenidonePirfenidone may decrease the antihypertensive activities of Alprenolol.Investigational
PirlindolePirlindole may increase the hypotensive activities of Alprenolol.Approved
PiroxicamPiroxicam may decrease the antihypertensive activities of Alprenolol.Approved, Investigational
PivhydrazinePivhydrazine may increase the hypotensive activities of Alprenolol.Withdrawn
PolythiazideAlprenolol may increase the hypotensive activities of Polythiazide.Approved
PrazosinAlprenolol may increase the orthostatic hypotensive activities of Prazosin.Approved
PrimaquineThe metabolism of Alprenolol can be decreased when combined with Primaquine.Approved
PrimidoneThe serum concentration of Alprenolol can be decreased when it is combined with Primidone.Approved, Vet Approved
ProcaterolAlprenolol may decrease the bronchodilatory activities of Procaterol.Approved
ProchlorperazineProchlorperazine may increase the hypotensive activities of Alprenolol.Approved, Vet Approved
PromazineThe metabolism of Alprenolol can be decreased when combined with Promazine.Approved, Vet Approved
PromethazinePromethazine may increase the hypotensive activities of Alprenolol.Approved
PropacetamolPropacetamol may decrease the antihypertensive activities of Alprenolol.Approved
PropafenoneThe serum concentration of Alprenolol can be increased when it is combined with Propafenone.Approved
PropiopromazinePropiopromazine may increase the hypotensive activities of Alprenolol.Vet Approved
PropranololPropranolol may increase the hypotensive activities of Alprenolol.Approved, Investigational
PseudoephedrinePseudoephedrine may increase the atrioventricular blocking (AV block) activities of Alprenolol.Approved
PTC299PTC299 may decrease the antihypertensive activities of Alprenolol.Investigational
PyridostigminePyridostigmine may increase the bradycardic activities of Alprenolol.Approved
QuinaprilAlprenolol may increase the hypotensive activities of Quinapril.Approved, Investigational
QuinidineThe metabolism of Alprenolol can be decreased when combined with Quinidine.Approved
QuinineQuinine may increase the hypotensive activities of Alprenolol.Approved
RamiprilRamipril may increase the hypotensive activities of Alprenolol.Approved
RanolazineThe metabolism of Alprenolol can be decreased when combined with Ranolazine.Approved, Investigational
RasagilineRasagiline may increase the hypotensive activities of Alprenolol.Approved
RegorafenibRegorafenib may increase the bradycardic activities of Alprenolol.Approved
RemifentanilRemifentanil may increase the bradycardic activities of Alprenolol.Approved
RemikirenRemikiren may increase the hypotensive activities of Alprenolol.Approved
RescinnamineAlprenolol may increase the hypotensive activities of Rescinnamine.Approved
ReserpineReserpine may increase the hypotensive activities of Alprenolol.Approved
ResveratrolResveratrol may decrease the antihypertensive activities of Alprenolol.Experimental, Investigational
RifampicinThe serum concentration of Alprenolol can be decreased when it is combined with Rifampicin.Approved
RifapentineThe serum concentration of Alprenolol can be decreased when it is combined with Rifapentine.Approved
RilmenidineAlprenolol may increase the hypotensive activities of Rilmenidine.Investigational
RiociguatAlprenolol may increase the hypotensive activities of Riociguat.Approved
RisperidoneRisperidone may increase the atrioventricular blocking (AV block) activities of Alprenolol.Approved, Investigational
RitodrineAlprenolol may decrease the bronchodilatory activities of Ritodrine.Approved
RitonavirThe metabolism of Alprenolol can be decreased when combined with Ritonavir.Approved, Investigational
RituximabAlprenolol may increase the hypotensive activities of Rituximab.Approved
RivastigmineRivastigmine may increase the bradycardic activities of Alprenolol.Approved, Investigational
RofecoxibRofecoxib may decrease the antihypertensive activities of Alprenolol.Investigational, Withdrawn
RolapitantThe metabolism of Alprenolol can be decreased when combined with Rolapitant.Approved
RopiniroleRopinirole may increase the atrioventricular blocking (AV block) activities of Alprenolol.Approved, Investigational
SafrazineSafrazine may increase the hypotensive activities of Alprenolol.Withdrawn
SalbutamolAlprenolol may decrease the bronchodilatory activities of Salbutamol.Approved, Vet Approved
SalicylamideSalicylamide may decrease the antihypertensive activities of Alprenolol.Approved
Salicylic acidSalicylic acid may decrease the antihypertensive activities of Alprenolol.Approved, Vet Approved
SalmeterolAlprenolol may decrease the bronchodilatory activities of Salmeterol.Approved
SalsalateSalsalate may decrease the antihypertensive activities of Alprenolol.Approved
SaprisartanAlprenolol may increase the hypotensive activities of Saprisartan.Experimental
SecobarbitalThe serum concentration of Alprenolol can be decreased when it is combined with Secobarbital.Approved, Vet Approved
SelegilineSelegiline may increase the hypotensive activities of Alprenolol.Approved, Investigational, Vet Approved
SelexipagAlprenolol may increase the hypotensive activities of Selexipag.Approved
SeratrodastSeratrodast may decrease the antihypertensive activities of Alprenolol.Approved, Investigational
SertralineThe metabolism of Alprenolol can be decreased when combined with Sertraline.Approved
SildenafilSildenafil may increase the antihypertensive activities of Alprenolol.Approved, Investigational
SilodosinAlprenolol may increase the orthostatic hypotensive activities of Silodosin.Approved
SitaxentanAlprenolol may increase the hypotensive activities of Sitaxentan.Approved, Investigational, Withdrawn
SpiraprilAlprenolol may increase the hypotensive activities of Spirapril.Approved
SRT501SRT501 may decrease the antihypertensive activities of Alprenolol.Investigational
StiripentolThe metabolism of Alprenolol can be decreased when combined with Stiripentol.Approved
SufentanilSufentanil may increase the bradycardic activities of Alprenolol.Approved, Investigational
SulfasalazineSulfasalazine may decrease the antihypertensive activities of Alprenolol.Approved
SulindacSulindac may decrease the antihypertensive activities of Alprenolol.Approved
SuprofenSuprofen may decrease the antihypertensive activities of Alprenolol.Approved, Withdrawn
TacrineTacrine may increase the bradycardic activities of Alprenolol.Withdrawn
TadalafilTadalafil may increase the antihypertensive activities of Alprenolol.Approved, Investigational
TamsulosinAlprenolol may increase the orthostatic hypotensive activities of Tamsulosin.Approved, Investigational
TelmisartanAlprenolol may increase the hypotensive activities of Telmisartan.Approved, Investigational
TemocaprilAlprenolol may increase the hypotensive activities of Temocapril.Experimental, Investigational
TenoxicamTenoxicam may decrease the antihypertensive activities of Alprenolol.Approved
TepoxalinTepoxalin may decrease the antihypertensive activities of Alprenolol.Vet Approved
TerazosinAlprenolol may increase the orthostatic hypotensive activities of Terazosin.Approved
TerbinafineThe metabolism of Alprenolol can be decreased when combined with Terbinafine.Approved, Investigational, Vet Approved
TerbutalineAlprenolol may decrease the bronchodilatory activities of Terbutaline.Approved
TeriflunomideTeriflunomide may decrease the antihypertensive activities of Alprenolol.Approved
TerlipressinAlprenolol may increase the hypotensive activities of Terlipressin.Approved, Investigational
TheophyllineAlprenolol may decrease the bronchodilatory activities of Theophylline.Approved
ThiamylalThe serum concentration of Alprenolol can be decreased when it is combined with Thiamylal.Approved, Vet Approved
ThiethylperazineThiethylperazine may increase the hypotensive activities of Alprenolol.Withdrawn
ThiopentalThe serum concentration of Alprenolol can be decreased when it is combined with Thiopental.Approved, Vet Approved
ThioridazineThe metabolism of Alprenolol can be decreased when combined with Thioridazine.Approved
Tiaprofenic acidTiaprofenic acid may decrease the antihypertensive activities of Alprenolol.Approved
TiboloneAlprenolol may increase the hypotensive activities of Tibolone.Approved
TiclopidineThe metabolism of Alprenolol can be decreased when combined with Ticlopidine.Approved
TicrynafenAlprenolol may increase the hypotensive activities of Ticrynafen.Withdrawn
TimololTimolol may increase the hypotensive activities of Alprenolol.Approved
TinoridineTinoridine may decrease the antihypertensive activities of Alprenolol.Investigational
TipranavirThe metabolism of Alprenolol can be decreased when combined with Tipranavir.Approved, Investigational
TizanidineTizanidine may increase the atrioventricular blocking (AV block) activities of Alprenolol.Approved
TolazamideAlprenolol may increase the hypoglycemic activities of Tolazamide.Approved
TolazolineTolazoline may increase the hypotensive activities of Alprenolol.Approved, Vet Approved
TolbutamideAlprenolol may increase the hypoglycemic activities of Tolbutamide.Approved
Tolfenamic AcidTolfenamic Acid may decrease the antihypertensive activities of Alprenolol.Approved
TolmetinTolmetin may decrease the antihypertensive activities of Alprenolol.Approved
ToloxatoneToloxatone may increase the hypotensive activities of Alprenolol.Approved
TorasemideTorasemide may increase the hypotensive activities of Alprenolol.Approved
TrandolaprilTrandolapril may increase the hypotensive activities of Alprenolol.Approved
TranilastTranilast may decrease the antihypertensive activities of Alprenolol.Approved, Investigational
Trans-2-PhenylcyclopropylamineTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Alprenolol.Experimental
TranylcypromineThe metabolism of Alprenolol can be decreased when combined with Tranylcypromine.Approved
TravoprostTravoprost may increase the hypotensive activities of Alprenolol.Approved
TreprostinilTreprostinil may increase the hypotensive activities of Alprenolol.Approved, Investigational
TrichlorfonTrichlorfon may increase the bradycardic activities of Alprenolol.Vet Approved
TrichlormethiazideAlprenolol may increase the hypotensive activities of Trichlormethiazide.Approved, Vet Approved
TrifluoperazineTrifluoperazine may increase the hypotensive activities of Alprenolol.Approved
TriflupromazineTriflupromazine may increase the hypotensive activities of Alprenolol.Approved, Vet Approved
TrimazosinAlprenolol may increase the orthostatic hypotensive activities of Trimazosin.Experimental
TrimethaphanAlprenolol may increase the hypotensive activities of Trimethaphan.Approved
Trisalicylate-cholineTrisalicylate-choline may decrease the antihypertensive activities of Alprenolol.Approved
TubocurarineTubocurarine may increase the bradycardic activities of Alprenolol.Approved
UdenafilUdenafil may increase the antihypertensive activities of Alprenolol.Approved, Investigational
UnoprostoneAlprenolol may increase the hypotensive activities of Unoprostone.Approved
ValdecoxibValdecoxib may decrease the antihypertensive activities of Alprenolol.Investigational, Withdrawn
ValsartanValsartan may increase the hypotensive activities of Alprenolol.Approved, Investigational
VardenafilVardenafil may increase the antihypertensive activities of Alprenolol.Approved
VareniclineThe risk or severity of adverse effects can be increased when Alprenolol is combined with Varenicline.Approved, Investigational
VenlafaxineThe metabolism of Alprenolol can be decreased when combined with Venlafaxine.Approved
VerapamilVerapamil may increase the hypotensive activities of Alprenolol.Approved
VilanterolAlprenolol may decrease the bronchodilatory activities of Vilanterol.Approved
VinpocetineAlprenolol may increase the hypotensive activities of Vinpocetine.Investigational
XylometazolineXylometazoline may increase the atrioventricular blocking (AV block) activities of Alprenolol.Approved
YohimbineYohimbine may decrease the antihypertensive activities of Alprenolol.Approved, Vet Approved
ZaltoprofenZaltoprofen may decrease the antihypertensive activities of Alprenolol.Approved
ZileutonZileuton may decrease the antihypertensive activities of Alprenolol.Approved, Investigational, Withdrawn
ZimelidineThe serum concentration of Alprenolol can be increased when it is combined with Zimelidine.Withdrawn
ZiprasidoneThe metabolism of Alprenolol can be decreased when combined with Ziprasidone.Approved
ZomepiracZomepirac may decrease the antihypertensive activities of Alprenolol.Withdrawn
Food InteractionsNot Available
References
Synthesis Reference

http://www.google.com.mx/patents/US3466376

General References
  1. Hold KM, de Boer D, Bos KL, van Ooijen RD, Zuidema J, Maes RA: Enantioselective quantitation of (R)- and (S)-alprenolol by gas chromatography-mass spectrometry in human saliva an plasma. J Chromatogr Sci. 1996 Jan;34(1):13-9. [PubMed:8586675 ]
  2. Himori N, Ishimori T, Izumi A, Hiramatsu Y: Effects of beta-adrenoceptor blocking agents, pindolol, alprenolol and practolol on blood pressure and heart rate in conscious renal hypertensive dogs. Arch Int Pharmacodyn Ther. 1977 Jan;225(1):152-65. [PubMed:15525 ]
External Links
ATC CodesC07AA01
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelNot Available
MSDSDownload (28.7 KB)
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9831
Blood Brain Barrier-0.9394
Caco-2 permeable+0.8866
P-glycoprotein substrateSubstrate0.6064
P-glycoprotein inhibitor IInhibitor0.5066
P-glycoprotein inhibitor IINon-inhibitor0.8382
Renal organic cation transporterNon-inhibitor0.8305
CYP450 2C9 substrateNon-substrate0.824
CYP450 2D6 substrateSubstrate0.882
CYP450 3A4 substrateNon-substrate0.7469
CYP450 1A2 substrateInhibitor0.9106
CYP450 2C9 inhibitorNon-inhibitor0.9071
CYP450 2D6 inhibitorInhibitor0.8931
CYP450 2C19 inhibitorNon-inhibitor0.9025
CYP450 3A4 inhibitorNon-inhibitor0.8839
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.8933
Ames testNon AMES toxic0.9133
CarcinogenicityNon-carcinogens0.9106
BiodegradationNot ready biodegradable0.9646
Rat acute toxicity2.5069 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.8664
hERG inhibition (predictor II)Non-inhibitor0.6946
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
PackagersNot Available
Dosage formsNot Available
PricesNot Available
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US3466376 No1966-06-171986-06-17Us
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point107-109 °CPhysProp
water solubility547 mg/LNot Available
logP3.10HANSCH,C ET AL. (1995)
Caco2 permeability-4.62ADME Research, USCD
Predicted Properties
PropertyValueSource
Water Solubility0.188 mg/mLALOGPS
logP2.59ALOGPS
logP2.69ChemAxon
logS-3.1ALOGPS
pKa (Strongest Acidic)14.09ChemAxon
pKa (Strongest Basic)9.67ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area41.49 Å2ChemAxon
Rotatable Bond Count8ChemAxon
Refractivity74.66 m3·mol-1ChemAxon
Polarizability29.38 Å3ChemAxon
Number of Rings1ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Download (3.94 KB)
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as phenylpropenes. These are compounds containing a phenylpropene moiety, which consists of a propene substituent bound to a phenyl group.
KingdomOrganic compounds
Super ClassBenzenoids
ClassBenzene and substituted derivatives
Sub ClassPhenylpropenes
Direct ParentPhenylpropenes
Alternative Parents
Substituents
  • Phenylpropene
  • Phenol ether
  • Alkyl aryl ether
  • Secondary alcohol
  • 1,2-aminoalcohol
  • Secondary amine
  • Ether
  • Secondary aliphatic amine
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Amine
  • Alcohol
  • Aromatic homomonocyclic compound
Molecular FrameworkAromatic homomonocyclic compounds
External DescriptorsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Receptor signaling protein activity
Specific Function:
Beta-adrenergic receptors mediate the catecholamine-induced activation of adenylate cyclase through the action of G proteins. This receptor binds epinephrine and norepinephrine with approximately equal affinity. Mediates Ras activation through G(s)-alpha- and cAMP-mediated signaling.
Gene Name:
ADRB1
Uniprot ID:
P08588
Molecular Weight:
51322.1 Da
References
  1. Surman AJ, Doggrell SA: Alprenolol and bromoacetylalprenololmenthane are competitive slowly reversible antagonists at the beta 1-adrenoceptors of rat left atria. J Cardiovasc Pharmacol. 1993 Jan;21(1):35-9. [PubMed:7678677 ]
  2. De Ponti F, Cosentino M, Costa A, Girani M, Gibelli G, D'Angelo L, Frigo G, Crema A: Inhibitory effects of SR 58611A on canine colonic motility: evidence for a role of beta 3-adrenoceptors. Br J Pharmacol. 1995 Apr;114(7):1447-53. [PubMed:7606348 ]
  3. Varma DR, Shen H, Deng XF, Peri KG, Chemtob S, Mulay S: Inverse agonist activities of beta-adrenoceptor antagonists in rat myocardium. Br J Pharmacol. 1999 Jun;127(4):895-902. [PubMed:10433496 ]
  4. Brahmadevara N, Shaw AM, MacDonald A: Evidence against beta 3-adrenoceptors or low affinity state of beta 1-adrenoceptors mediating relaxation in rat isolated aorta. Br J Pharmacol. 2003 Jan;138(1):99-106. [PubMed:12522078 ]
  5. Im MJ, Holzhofer A, Bottinger H, Pfeuffer T, Helmreich EJ: Interactions of pure beta gamma-subunits of G-proteins with purified beta 1-adrenoceptor. FEBS Lett. 1988 Jan 25;227(2):225-9. [PubMed:2828119 ]
  6. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Protein homodimerization activity
Specific Function:
Beta-adrenergic receptors mediate the catecholamine-induced activation of adenylate cyclase through the action of G proteins. The beta-2-adrenergic receptor binds epinephrine with an approximately 30-fold greater affinity than it does norepinephrine.
Gene Name:
ADRB2
Uniprot ID:
P07550
Molecular Weight:
46458.32 Da
References
  1. Brodde OE, Wang XL, O'Hara N, Daul A, Schiess W: Effect of propranolol, alprenolol, pindolol, and bopindolol on beta 2-adrenoceptor density in human lymphocytes. J Cardiovasc Pharmacol. 1986;8 Suppl 6:S70-3. [PubMed:2439825 ]
  2. Brodde OE, Daul A, Stuka N, O'Hara N, Borchard U: Effects of beta-adrenoceptor antagonist administration on beta 2-adrenoceptor density in human lymphocytes. The role of the "intrinsic sympathomimetic activity". Naunyn Schmiedebergs Arch Pharmacol. 1985 Feb;328(4):417-22. [PubMed:2859531 ]
  3. Abrahamsson T: The beta 1- and beta 2-adrenoceptor stimulatory effects of alprenolol, oxprenolol and pindolol: a study in the isolated right atrium and uterus of the rat. Br J Pharmacol. 1986 Apr;87(4):657-64. [PubMed:2871880 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Serotonin receptor activity
Specific Function:
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors, such as adenylate cyclase. Beta-arrestin family members inhibit signaling via G pro...
Gene Name:
HTR1A
Uniprot ID:
P08908
Molecular Weight:
46106.335 Da
References
  1. Millan MJ, Rivet JM, Canton H, Lejeune F, Bervoets K, Brocco M, Gobert A, Lefebvre de Ladonchamps B, Le Marouille-Girardon S, Verriele L, et al.: S 14671: a naphtylpiperazine 5-hydroxytryptamine1A agonist of exceptional potency and high efficacy possessing antagonist activity at 5-hydroxytryptamine1C/2 receptors. J Pharmacol Exp Ther. 1992 Aug;262(2):451-63. [PubMed:1323650 ]
  2. Darmani NA: Role of the inhibitory adrenergic alpha 2 and serotonergic 5-HT1A components of cocaine's actions on the DOI-induced head-twitch response in 5-HT2-receptor supersensitive mice. Pharmacol Biochem Behav. 1993 Jun;45(2):269-74. [PubMed:8392199 ]
  3. Kuipers W, Link R, Standaar PJ, Stoit AR, Van Wijngaarden I, Leurs R, Ijzerman AP: Study of the interaction between aryloxypropanolamines and Asn386 in helix VII of the human 5-hydroxytryptamine1A receptor. Mol Pharmacol. 1997 May;51(5):889-96. [PubMed:9145928 ]
  4. Misane I, Johansson C, Ogren SO: Analysis of the 5-HT1A receptor involvement in passive avoidance in the rat. Br J Pharmacol. 1998 Oct;125(3):499-509. [PubMed:9806333 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic antidepressants.
Gene Name:
CYP2D6
Uniprot ID:
P10635
Molecular Weight:
55768.94 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  2. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on December 08, 2016 11:11